David Thomae
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Thomae has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Pierre Seck
7 shared publicationsEnrico Perspicace
5 shared publicationsGilbert Kirsch
5 shared publicationsStéphanie Hesse
5 shared publications- Gilbert Kirsch
Laboratoire de Chimie Bioorganique et Analytique (LCBA), Université Hassan II Mohammedia-Casablanca, FST-Mohammedia, BP 146, 20800 Mohammedia, Morocco
4 shared publications - Pierre Seck
Laboratoire de Chimie, Faculté des Sciences, de la Technologie et de la Communication, Université du Luxembourg, 162a, avenue de la Faïencerie, 1511 Luxembourg, Luxembourg
4 shared publications
Latest Publications
- 20 June 2016
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 19 (1) , 109-119
Evaluation of [18F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal Cancer
Purpose In oncology, positron emission tomography imaging using dedicated tracers as biomarkers may assist in early evaluation of therapy efficacy. Using 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT), we investigated the early effects of chemotherapeutic treatment on cancer cell proliferation in a BRAF-mutated colorectal cancer xenograft model. Procedures Colo205 subcutaneously inoculated animals underwent 90-min dynamic imaging before and 24 h after treatment with vehicle (control), cetuximab (resistant) or irinotecan (sensitive). Total distribution volume was quantified from dynamic data, and standardized uptake values as well as tumor-to-blood ratios were calculated from static images averaged over the last 20 min. In vivo imaging data was correlated with ex vivo proliferation and thymidine metabolism proteins. Results All imaging parameters showed a significant post-treatment decrease from [18F]FLT baseline uptake for the irinotecan group (p ≤ 0.001) as compared with the cetuximab and vehicle group and correlated strongly with each other (p ≤ 0.0001). In vivo data were in agreement with Ki67 staining, showing a significantly lower percentage of Ki67-positive cells in the irinotecan group as compared with other groups (p ≤ 0.0001). Tumor expression of thymidine kinase 1 phosphorylated on serine 13, thymidylate synthase, and thymidine phosphorylase remained unaffected, while thymidine kinase 1 expression was, surprisingly, significantly higher in irinotecan-treated animals (p ≤ 0.01). In contrast, tumor ATP levels were lowest in this group. Conclusions [18F]FLT positron emission tomography was found to be a suitable biomarker of early tumor response to anti-proliferative treatment, with static imaging not being inferior to full compartmental analysis in our xenograft model. The dynamics of thymidine kinase 1 protein expression and protein activity in low ATP environments merits further investigation.
- 20 June 2016
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 19 (1) , 109-119
Evaluation of [18F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal Cancer
Purpose In oncology, positron emission tomography imaging using dedicated tracers as biomarkers may assist in early evaluation of therapy efficacy. Using 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT), we investigated the early effects of chemotherapeutic treatment on cancer cell proliferation in a BRAF-mutated colorectal cancer xenograft model. Procedures Colo205 subcutaneously inoculated animals underwent 90-min dynamic imaging before and 24 h after treatment with vehicle (control), cetuximab (resistant) or irinotecan (sensitive). Total distribution volume was quantified from dynamic data, and standardized uptake values as well as tumor-to-blood ratios were calculated from static images averaged over the last 20 min. In vivo imaging data was correlated with ex vivo proliferation and thymidine metabolism proteins. Results All imaging parameters showed a significant post-treatment decrease from [18F]FLT baseline uptake for the irinotecan group (p ≤ 0.001) as compared with the cetuximab and vehicle group and correlated strongly with each other (p ≤ 0.0001). In vivo data were in agreement with Ki67 staining, showing a significantly lower percentage of Ki67-positive cells in the irinotecan group as compared with other groups (p ≤ 0.0001). Tumor expression of thymidine kinase 1 phosphorylated on serine 13, thymidylate synthase, and thymidine phosphorylase remained unaffected, while thymidine kinase 1 expression was, surprisingly, significantly higher in irinotecan-treated animals (p ≤ 0.01). In contrast, tumor ATP levels were lowest in this group. Conclusions [18F]FLT positron emission tomography was found to be a suitable biomarker of early tumor response to anti-proliferative treatment, with static imaging not being inferior to full compartmental analysis in our xenograft model. The dynamics of thymidine kinase 1 protein expression and protein activity in low ATP environments merits further investigation.
- 1 December 2015
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 42 (12) , 975-981
Synthesis and preclinical evaluation of an 18 F labeled PDE7 inhibitor for PET neuroimaging
- 1 December 2015
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 42 (12) , 975-981
Synthesis and preclinical evaluation of an 18 F labeled PDE7 inhibitor for PET neuroimaging
- 25 August 2014
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 57 (10) , 611-614
Automated one‐step radiosynthesis of the CB1 receptor imaging agent [18F]MK‐9470
The fluorine‐18‐labeled positron emission tomography (PET) radiotracer [18F]MK‐9470 is a selective, high affinity inverse agonist that has been used to image the cannabinoid receptor type 1 in human brain in healthy and disease states. This report describes a simplified, one‐step [18F]radiofluorination approach using a GE TRACERlab FXFN module for the routine production of this tracer. The one‐step synthesis, by [18F]fluoride displacement of a primary tosylate precursor, gives a six‐fold increase in yield over the previous two‐step method employing O‐alkylation of a phenol precursor with 1,2‐[18F]fluorobromoethane. The average radiochemical yield of [18F]MK‐9470 using the one‐step method was 30.3 ± 11.7% (n = 12), with specific activity in excess of 6 Ci/µmol and radiochemical purity of 97.2 ± 1.5% (n = 12), in less than 60 min. This simplified, high yielding, automated process was validated for routine GMP production of [18F]MK‐9470 for clinical studies.
- 25 August 2014
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 57 (10) , 611-614
Automated one‐step radiosynthesis of the CB1 receptor imaging agent [18F]MK‐9470
The fluorine‐18‐labeled positron emission tomography (PET) radiotracer [18F]MK‐9470 is a selective, high affinity inverse agonist that has been used to image the cannabinoid receptor type 1 in human brain in healthy and disease states. This report describes a simplified, one‐step [18F]radiofluorination approach using a GE TRACERlab FXFN module for the routine production of this tracer. The one‐step synthesis, by [18F]fluoride displacement of a primary tosylate precursor, gives a six‐fold increase in yield over the previous two‐step method employing O‐alkylation of a phenol precursor with 1,2‐[18F]fluorobromoethane. The average radiochemical yield of [18F]MK‐9470 using the one‐step method was 30.3 ± 11.7% (n = 12), with specific activity in excess of 6 Ci/µmol and radiochemical purity of 97.2 ± 1.5% (n = 12), in less than 60 min. This simplified, high yielding, automated process was validated for routine GMP production of [18F]MK‐9470 for clinical studies.
- 1 July 2014
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 41 (6) , 477-487
Synthesis and in vivo preclinical evaluation of an 18F labeled uPA inhibitor as a potential PET imaging agent
- 1 July 2014
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 41 (6) , 477-487
Synthesis and in vivo preclinical evaluation of an 18F labeled uPA inhibitor as a potential PET imaging agent
- 1 July 2014
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 41 (6) , 513-523
In vivo evaluation of 18F-labeled TCO for pre-targeted PET imaging in the brain
- 1 July 2014
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 41 (6) , 513-523
In vivo evaluation of 18F-labeled TCO for pre-targeted PET imaging in the brain
- Open Access
- 4 June 2014
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 55 (8) , 1297-1304
In Vivo Assessment and Dosimetry of 2 Novel PDE10A PET Radiotracers in Humans: 18F-MNI-659 and 18F-MNI-654
Phosphodiesterase (PDE) 10A is an enzyme involved in the regulation of cyclic adenosine monophosphate and cyclic guanosine monophosphate and is highly expressed in medium-sized spiny neurons of the striatum, making it an attractive target for novel therapies for a variety of neurologic and psychiatric disorders that involve striatal function. Potential ligands for PET imaging of PDE10A have been reported. Here, we report the first-in-human characterization of 2 new PDE10A radioligands, 2-(2-(3-(1-(2-fluoroethyl)-1H-indazol-6-yl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione (18F-MNI-654) and 2-(2-(3-(4-(2-fluoroethoxy)phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione (18F-MNI-659), with the goal of selecting the best one for use in future studies interrogating pathophysiologic changes in neuropsychiatric disorders and aiding pharmaceutical development targeting PDE10A. Methods: Eleven healthy volunteers participated in this study (18F-MNI-654 test–retest, 2 men; 18F-MNI-659 test–retest, 4 men and 1 woman; 18F-MNI-659 dosimetry, 2 men and 2 women). Brain PET images were acquired over 5.5 h for 18F-MNI-654 and over 3.5 h for 18F-MNI-659, and pharmacokinetic modeling with plasma- and reference-region (cerebellar cortex)-based methods was performed. Whole-body PET images were acquired over 6 h for 18F-MNI-659 and radiation dosimetry estimated with OLINDA. Results: Both radiotracers were similarly metabolized, with about 20% of intact parent remaining at 120 min after injection. PET time–activity data demonstrated that 18F-MNI-654 kinetics were much slower than 18F-MNI-659 kinetics. For 18F-MNI-659, there was good agreement between the Logan and simplified reference tissue models for nondisplaceable binding potential (BPND), supporting noninvasive quantification, with test–retest variability less than 10% and intraclass correlation greater than 0.9. The 18F-MNI-659 effective dose was estimated at 0.024 mSv/MBq. Conclusion: PET imaging in the human brain with 2 novel PDE10A 18F tracers is being reported. Noninvasive quantification of 18F-MNI-659 with the simplified reference tissue model using the cerebellum as a reference is possible. In addition, 18F-MNI-659 kinetics are fast enough for a good estimate of BPND with 90 min of data, with values around 3.0 in the basal ganglia. Finally, 18F-MNI-659 dosimetry is favorable and consistent with values reported for other PET radiotracers currently used in humans.
- 4 June 2014
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 55 (8) , 1297-1304
Open AccessIn Vivo Assessment and Dosimetry of 2 Novel PDE10A PET Radiotracers in Humans: 18F-MNI-659 and 18F-MNI-654
Phosphodiesterase (PDE) 10A is an enzyme involved in the regulation of cyclic adenosine monophosphate and cyclic guanosine monophosphate and is highly expressed in medium-sized spiny neurons of the striatum, making it an attractive target for novel therapies for a variety of neurologic and psychiatric disorders that involve striatal function. Potential ligands for PET imaging of PDE10A have been reported. Here, we report the first-in-human characterization of 2 new PDE10A radioligands, 2-(2-(3-(1-(2-fluoroethyl)-1H-indazol-6-yl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione (18F-MNI-654) and 2-(2-(3-(4-(2-fluoroethoxy)phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione (18F-MNI-659), with the goal of selecting the best one for use in future studies interrogating pathophysiologic changes in neuropsychiatric disorders and aiding pharmaceutical development targeting PDE10A. Methods: Eleven healthy volunteers participated in this study (18F-MNI-654 test–retest, 2 men; 18F-MNI-659 test–retest, 4 men and 1 woman; 18F-MNI-659 dosimetry, 2 men and 2 women). Brain PET images were acquired over 5.5 h for 18F-MNI-654 and over 3.5 h for 18F-MNI-659, and pharmacokinetic modeling with plasma- and reference-region (cerebellar cortex)-based methods was performed. Whole-body PET images were acquired over 6 h for 18F-MNI-659 and radiation dosimetry estimated with OLINDA. Results: Both radiotracers were similarly metabolized, with about 20% of intact parent remaining at 120 min after injection. PET time–activity data demonstrated that 18F-MNI-654 kinetics were much slower than 18F-MNI-659 kinetics. For 18F-MNI-659, there was good agreement between the Logan and simplified reference tissue models for nondisplaceable binding potential (BPND), supporting noninvasive quantification, with test–retest variability less than 10% and intraclass correlation greater than 0.9. The 18F-MNI-659 effective dose was estimated at 0.024 mSv/MBq. Conclusion: PET imaging in the human brain with 2 novel PDE10A 18F tracers is being reported. Noninvasive quantification of 18F-MNI-659 with the simplified reference tissue model using the cerebellum as a reference is possible. In addition, 18F-MNI-659 kinetics are fast enough for a good estimate of BPND with 90 min of data, with values around 3.0 in the basal ganglia. Finally, 18F-MNI-659 dosimetry is favorable and consistent with values reported for other PET radiotracers currently used in humans.
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S112
Poster #S67 IN VIVO CHARACTERIZATION OF THE PDE10A PET TRACER [18F]MNI-659
- 1 April 2014
- Published by Elsevier in Schizophrenia Research
- Vol. 153, S112
Poster #S67 IN VIVO CHARACTERIZATION OF THE PDE10A PET TRACER [18F]MNI-659
- 15 April 2013
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2013 (16) , 3328-3336
Extending the Scope of the Aza‐Fischer Synthesis of 4‐ and 6‐Azaindoles
- 15 April 2013
- Published by Wiley in European Journal of Organic Chemistry
- Vol. 2013 (16) , 3328-3336
Extending the Scope of the Aza‐Fischer Synthesis of 4‐ and 6‐Azaindoles
- Open Access
- 22 May 2012
- Published by ARKAT USA, Inc. in Arkivoc
- Vol. 2012 (3) , 431-441
Synthesis of new selenophene and thiazole analogues of the Tacrine series
- 22 May 2012
- Published by ARKAT USA, Inc. in Arkivoc
- Vol. 2012 (3) , 431-441
Open AccessSynthesis of new selenophene and thiazole analogues of the Tacrine series
- 1 February 2010
- Published by Bentham Science Publishers Ltd. in Current Organic Synthesis
- Vol. 7 (1) , 44-61
Utility of Hydrogen Selenide and Its Related Salts for the Synthesis of Selenium- Containing Heterocycles
Interest in organoselenium chemistry has been increasing for the last 25 years. This paper reviews the use of sodium selenide and its hydrogenated form (NaHSe, H2Se) for the preparation of a wide variety of selenium-containing heterocycles.
- 1 February 2010
- Published by Bentham Science Publishers Ltd. in Current Organic Synthesis
- Vol. 7 (1) , 44-61
Utility of Hydrogen Selenide and Its Related Salts for the Synthesis of Selenium- Containing Heterocycles
Interest in organoselenium chemistry has been increasing for the last 25 years. This paper reviews the use of sodium selenide and its hydrogenated form (NaHSe, H2Se) for the preparation of a wide variety of selenium-containing heterocycles.